Recombinant Human ACBD4 protein

ACBD4 (Acyl-CoA-Binding Domain-Containing Protein 4) is a member of the ACBD protein family, characterized by the presence of an acyl-CoA-binding domain (ACB domain) that facilitates interactions with acyl-CoA esters, key intermediates in lipid metabolism. While the ACBD family is broadly implicated in lipid biosynthesis, membrane trafficking, and organelle dynamics, ACBD4 remains less studied compared to its well-characterized homologs like ACBD1 (also known as diazepam-binding inhibitor, DBI) or ACBD3. Existing studies suggest ACBD4 may localize to the Golgi apparatus or endoplasmic reticulum, potentially regulating lipid transport or membrane remodeling processes. Its precise physiological role, however, remains unclear, though its expression in tissues with high metabolic activity (e.g., liver, brain) hints at involvement in lipid homeostasis or signaling pathways.

Recombinant ACBD4 protein is typically produced using heterologous expression systems (e.g., E. coli, mammalian cells) to enable functional studies. Researchers employ it to investigate protein-protein interactions, lipid-binding specificity, and subcellular localization mechanisms. Emerging evidence links ACBD4 dysregulation to metabolic disorders and cancers, spurring interest in its potential as a therapeutic target. For instance, altered ACBD4 expression has been observed in hepatocellular carcinoma and neurodegenerative conditions, though mechanistic insights are still limited. Structural studies of recombinant ACBD4 aim to resolve its 3D conformation and ligand-binding pockets, which could inform drug design. Despite its understudied status, ACBD4 represents a promising candidate for exploring novel pathways in lipid biology and disease, warranting further investigation into its molecular functions and therapeutic relevance.